CelluGenix

CelluGenix is a clinical-stage biopharmaceutical company specializing in the development and commercialization of induced pluripotent stem cell (iPSC)-derived therapies. As the global commercialization partner of Allife Medicine, the company focuses on regenerative medicine solutions for critical conditions such as ischemic stroke and severe lower limb ischemia. Its lead programs, ALF201 and ALF202, utilize allogeneic endothelial progenitor cells (EPCs) to promote vascular repair, neuroprotection, and inflammation reduction. CelluGenix is currently conducting Phase 1 and 2 clinical trials in China and is expanding its regulatory and clinical footprint to the United States and the United Kingdom. The company also leverages an exosome platform to broaden its therapeutic reach into degenerative and metabolic diseases. Headquartered in Los Angeles, CelluGenix aims to establish global manufacturing facilities to support its advancing clinical pipeline.